Titre A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Protocole ID CA018-005
ClinicalTrials.gov ID NCT02996110
Type(s) de cancer Rein
Phase Phase II
Stade Maladie avancée ou métastatique
Type étude Traitement
Médicament Nivolumab, Ipilimumab, Relatlimab
Institution CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
   HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
      3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville Montréal
Investigateur(trice) principal(e) Dr Wilson Miller
Coordonnateur(trice) Gayathri Kuruba
514-340-8222 poste 26187
Statut Fermé
Critètes d'éligibilité
  • Advanced Renal Cell Carcinoma
  • Must have at least 1 lesion with measurable disease
  • Life expectancy of at least 3 months
Critètes d'exclusion
  • Patients/subjects with suspected or known central nervous system metastases unless adequately treated
  • Patients/subjects with autoimmune disease
  • Patients/subjects who need daily oxygen therapy